Affinité Instruments initiates a collaboration with the TRAC and CCAB to validate its flagship SPR instrument
February 1, 2016 – Surface Plasmon Resonance (SPR) is a gold standard technology used in drug development to collect pharmacokinetic information and screen for potential drugs. Despite the value provided by the technology to researchers, the expensive cost of acquisition and the complexity of operation of SPR instruments restrict its usage outside the pharmaceutical industry. Affinité Instrument, a spin-off of the Université de Montréal, has developed innovations that aim to make SPR accessible to academic laboratories and small start-ups. Their flagship device, the portable and 4-channel surface plasmon resonance (P4SPR) instrument, is designed to measure and monitor analytes such as proteins, DNA and even small molecules within complex media (e.g. serum, urine and water). The P4SPR was commercialized for research-based purposes in June 2015. In September 2015, the Centre for the Commercialization of Antibodies and Biologics (CCAB) agreed to validate the P4SPR’s analytical performance against a state-of-the-art SPR instrument. “The P4SPR’s ease of use and the accessibility of the instrument allowed it to fit into our regular operations with no down-time, accelerating analysis” said Dr. James Pan, CCAB VP of Product Development. The P4SPR is currently being tested by a professional team of scientists from the Toronto Recombinant Antibody Centre (TRAC).
For further information with regards to the device, please contact: Dr. Jean-François Masson, President: email@example.com, or visit the official Affinité Instruments P4SPR product website: http://affiniteinstruments.com/p4spr-features.